Financial Performance Expectations - The company expects a net profit of -76 million yuan for the year 2025, compared to -52 million yuan in the same period last year [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be -88 million yuan, down from -60 million yuan year-on-year [4]. - Basic earnings per share are expected to be -0.2390 yuan, compared to -0.1635 yuan in the previous year [4]. Reasons for Expected Loss - The primary reason for the expected loss is high fixed costs, particularly depreciation of fixed assets [6]. - The company anticipates a reduction in losses for 2025 compared to the previous year due to a decrease in the provision for fixed asset impairment [6]. Financial Data and Audit Status - The financial data in the earnings forecast has not been audited by the accounting firm, and the final figures will be confirmed in the 2025 annual report [7]. - The company has communicated with the accounting firm regarding the earnings forecast, and there are no significant discrepancies [5]. Investor Caution - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the financial data [8].
天圣制药(002872) - 2025 Q4 - 年度业绩预告